Preview Citation


Tempero, M. A.1*MD, Malafa, M. P.2MD, Chiorean, E.3*MD, Czito, B.4*MD, Scaife, C.5*MD, Narang, A. K.6*MD, Fountzilas, C.7*MD, Wolpin, B. M.8*MD, MPH, Al-Hawary, M.9MD, Asbun, H.10MD, Behrman, S. W.11MD, Benson, A. B.12MD, Binder, E.13MD, Cardin, D. B.14MD, Cha, C.15MD, Chung, V.16MD, Dillhoff, M.17MD, Dotan, E.18MD, Ferrone, C. R.19MD, Fisher, G.20MD, PhD, Hardacre, J.21MD, Hawkins, W. G.13MD, Ko, A. H.1MD, LoConte, N.22MD, Lowy, A. M.23MD, Moravek, C.24, Nakakura, E. K.1MD, O’Reilly, E. M.25MD, Obando, J.4MD, Reddy, S.26MD, Thayer, S.27MD, Wolff, R. A.28MD, Burns, J. L.29*, & Zuccarino-Catania, G.29*PhD. (2019). NCCN Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019, Journal of the National Comprehensive Cancer Network J Natl Compr Canc Netw, 17(3), 202-210. Retrieved Jun 17, 2019, from